Pluripotin treatment decreases leukemic burden in vivo and prolongs survival. The survival of NSGS mice transplanted with human AML cell lines MOLM13 (A) and MOLM13-RAS^G12V (B) is shown. One million MOLM13 and MOLM13-RAS^G12V cells were transplanted by tail vein injection in NSGS mice. Treatment with gilteritinib (100 mg/kg daily) and pluripotin (15 mg/kg daily) was started after 2 days of transplantation. Control mice were injected with vehicle, phosphate-buffered saline. shown are leukemic burden measured by cherry⁺ cells in mice recipients of MOLM13 (C) and MOLM13-RAS^G12V (D). Bar graph showing the percentage of leukemic cells determined by cherry⁺ cells using FACS in mice transplanted with MOLM13 (E) and MOLM13-RAS^G12V cell (F). Presented data are from 2 independent experiments (3 mice per group) shown as mean ± SD. ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001.